Identification of a graft versus host disease-associated human minor histocompatibility antigen

J M den Haan, N E Sherman, E Blokland, E Huczko, F Koning, J W Drijfhout, J Skipper, J Shabanowitz, D F Hunt, V H Engelhard

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Minor histocompatibility antigen disparities between human leukocyte antigen (HLA)-matched bone marrow donors and recipients are a major risk factor for graft versus host disease (GVHD). An HLA-A2.1-restricted cytotoxic T cell clone that recognized the minor histocompatibility antigen HA-2 was previously isolated from a patient with severe GVHD after HLA-identical bone marrow transplantation. The HLA-A2.1-bound peptide representing HA-2 has now been identified. This peptide appears to originate from a member of the non-filament-forming class I myosin family. Because HA-2 has a phenotype frequency of 95 percent in the HLA-A2.1-positive population, it is a candidate for immunotherapeutic intervention in bone marrow transplantation.

Original languageEnglish
Pages (from-to)1476-80
Number of pages5
JournalScience
Volume268
Issue number5216
Publication statusPublished - 9 Jun 1995

Cite this